Guardant Health, Inc. (NASDAQ:GH) Shares Purchased by Prudential Financial Inc.

Prudential Financial Inc. boosted its stake in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 2,235.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 229,870 shares of the company's stock after acquiring an additional 220,028 shares during the quarter. Prudential Financial Inc. owned about 0.19% of Guardant Health worth $7,023,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of GH. Vanguard Group Inc. grew its stake in shares of Guardant Health by 3.0% during the fourth quarter. Vanguard Group Inc. now owns 12,052,551 shares of the company's stock valued at $368,205,000 after acquiring an additional 350,606 shares in the last quarter. Fox Run Management L.L.C. purchased a new position in Guardant Health in the fourth quarter valued at about $369,000. KLP Kapitalforvaltning AS acquired a new stake in Guardant Health during the 4th quarter valued at approximately $758,000. Quantbot Technologies LP purchased a new stake in Guardant Health during the 4th quarter worth approximately $80,000. Finally, Summit Global Investments acquired a new position in shares of Guardant Health in the 4th quarter valued at approximately $630,000. Institutional investors and hedge funds own 92.60% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on GH. JPMorgan Chase & Co. lifted their price target on shares of Guardant Health from $50.00 to $55.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. The Goldman Sachs Group upped their target price on shares of Guardant Health from $49.00 to $56.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Stifel Nicolaus lifted their price target on Guardant Health from $45.00 to $53.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Piper Sandler upped their price objective on Guardant Health from $34.00 to $50.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Finally, Morgan Stanley lifted their target price on Guardant Health from $42.00 to $52.00 and gave the stock an "overweight" rating in a research report on Thursday, March 6th. Twenty research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $48.95.

Remove Ads

Guardant Health Stock Performance

Shares of NASDAQ:GH traded down $1.44 during trading hours on Friday, hitting $40.58. The stock had a trading volume of 1,891,349 shares, compared to its average volume of 2,128,511. The stock's fifty day simple moving average is $44.39 and its 200 day simple moving average is $34.82. The firm has a market capitalization of $5.01 billion, a price-to-earnings ratio of -11.40 and a beta of 1.45. Guardant Health, Inc. has a 1-year low of $15.81 and a 1-year high of $50.89.

Guardant Health (NASDAQ:GH - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.15). The business had revenue of $201.81 million during the quarter, compared to the consensus estimate of $192.50 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. As a group, research analysts anticipate that Guardant Health, Inc. will post -2.9 EPS for the current year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.